Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coviro.2020.08.003 http://scihub22266oqcxt.onion/10.1016/j.coviro.2020.08.003 32898764!7474593!32898764     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Virol 2020 ; 44 (ä): 145-153 Nephropedia Template TP {{tp|p=32898764|t=2020. A new generation of vaccines based on alphavirus self-amplifying RNA |pdf=|usr=}}{{32898764}} gab.com Text A new generation of vaccines based on alphavirus self-amplifying RNA JO: Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=32898764 #FOAvip DNA or mRNA vaccines have potential advantages over conventional vaccines since they are easier to manufacture and have higher safety profiles. In particular, self-amplifying RNA (saRNA) derived from alphavirus expression vectors has shown to be very efficient to induce humoral and cellular responses against many antigens in preclinical models, being superior to non-replicating mRNA and DNA. This is mainly due to the fact that saRNA can provide very high expression levels and simultaneously induces strong innate responses, potentiating immunity. saRNA can be administered as viral particles or DNA, but direct delivery as RNA represents a safer and more simple approach. Although saRNA can be delivered as naked RNA, in vivo transfection can be enhanced by electroporation or by complexing it with cationic lipids or polymers. Alphavirus saRNA could have broad application to vaccinate against human pathogens, including emerging ones like SARS-CoV-2, for which clinical trials have been recently initiated. Twit Text FOAVip A new generation of vaccines based on alphavirus self-amplifying RNA ????Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=32898764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32898764 #FOAvip English Wikipedia <ref>{{Cite pmid|32898764}}</ref> A new generation of vaccines based on alphavirus self-amplifying RNA #MMPMID32898764 Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Canete G; Vanrell L; Smerdou C Curr Opin Virol 2020[Oct]; 44 (ä): 145-153 PMID32898764show ga DNA or mRNA vaccines have potential advantages over conventional vaccines since they are easier to manufacture and have higher safety profiles. In particular, self-amplifying RNA (saRNA) derived from alphavirus expression vectors has shown to be very efficient to induce humoral and cellular responses against many antigens in preclinical models, being superior to non-replicating mRNA and DNA. This is mainly due to the fact that saRNA can provide very high expression levels and simultaneously induces strong innate responses, potentiating immunity. saRNA can be administered as viral particles or DNA, but direct delivery as RNA represents a safer and more simple approach. Although saRNA can be delivered as naked RNA, in vivo transfection can be enhanced by electroporation or by complexing it with cationic lipids or polymers. Alphavirus saRNA could have broad application to vaccinate against human pathogens, including emerging ones like SARS-CoV-2, for which clinical trials have been recently initiated. |Alphavirus/*genetics[MESH] |COVID-19 Vaccines/genetics/*immunology[MESH] |COVID-19/immunology/*prevention & control[MESH] |Humans[MESH] |RNA, Messenger/genetics[MESH] |SARS-CoV-2/*immunology[MESH]A new generation of vaccines based on alphavirus self-amplifying RNA (epmc).pdf DeepDyve Pubget Overpricing